Natco Pharma Ltd (NATCOPHARM) is currently trading at 782.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Natco Pharma is a vertically integrated, R&D‑focused pharmaceutical company that develops, manufactures and markets Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs), with a global footprint across 40+ countries, two R&D centres and state‑of‑the‑art manufacturing approved by major regulators including USFDA. The company focuses on complex, limited‑competition generics and niche therapies, maintaining a deep Para IV pipeline (28 filings, 20+ first‑to‑file opportunities) and a US portfolio of 40+ approved products; Natco emphasises multi‑site approvals, partner models and selective in‑house launches through its US subsidiary to improve margins and control. Recent strategic moves include a material stake acquisition in Adcock Ingram to accelerate African expansion, a Board‑approved demerger plan for Crop Health Sciences, and new domestic launches such as Semaglutide vials and Risdiplam, reflecting simultaneous scaling of branded generics, agrochemicals and advanced therapeutics. Financially, Natco reported consolidated FY26 revenue of INR 43,759 million and EBITDA of INR 17,341 million with a PAT of INR 14,185 million; FY26 margins moderated versus FY25 while the balance sheet shows significant investment accounted for using equity method (INR 22,757 million), reflecting strategic stakes and RoW consolidation.

Over the past 52 weeks, Natco Pharma Ltd has traded between a low of ₹774.00 and a high of ₹1,216.19. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Natco Pharma Ltd has a market capitalization of approximately 15,453.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Natco Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 15.24 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 15,453.13 Cr, Natco Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Natco Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Natco Pharma Ltd is 15.24. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Natco Pharma has fixed October 1, 2026 as the record date for determining shareholder eligibility for the rights issue.

Natco Pharma’s 43rd AGM is scheduled for September 30, 2026, at 11:00 am (IST).

Natco Pharma has approved a rights issue to raise up to ₹1,279.35 crore (also reported as ₹1,279.36 crore) at an issue price of ₹750 per share.

Natco Pharma has scheduled the board meeting for September 25, 2026 to decide the detailed terms of the proposed rights issue.